Interv Akut Kardiol. 2018;17(2):71-74 | DOI: 10.36290/kar.2018.040

Cardiogenic shock

Jiří Kettner
Klinika kardiologie, IKEM, Praha

Cardiogenic shock (CS) is a serious condition of systemic hypoperfusion due to impaired cardiac pump function, often resulting inmultiple organ failure. The most common cause of CS is left ventricular failure resulting from extensive acute myocardial infarction(AMI); other causes of CS include mechanical complications of AMI, right ventricular infarction, terminal-stage cardiomyopathy,arrhythmias, acute fulminant myocarditis, and post-cardiac arrest states. Despite early revascularization, the mortality of CS asa complication of AMI remains to be around 50%, making it one of the leading causes of death among the patients with AMI.Every patient with signs and symptoms of CS should be transferred to a specialist heart centre, allowing to perform immediateselective coronary angiography and possible revascularization using PCI for 24 hours and having specialist intensive care forthese patients with a possibility to provide short-term acute mechanical circulatory support (AMCS). Although the use of inotropicand vasopressor agents cannot be avoided, their long-term administration leads to severe adverse consequences, includingthe development of both ventricular and atrial arrhythmias, increased myocardial oxygen consumption, direct toxic effect oncardiomyocytes, and worse survival. For these reasons, the use of short-term percutaneous AMCS has been increasing. The issueof timing and of the most suitable type of this support in order to affect mortality remains unclear so far. Experience with an earlyuse of MCS in patients with terminal stage of chronic heart failure that resulted in improved survival also supports this notion inthose with CS due to AMI. The development of a specialized team of experts for the management of CS with a multidisciplinaryorganization is a reasonable condition for rational treatment and better outcomes, as in other life-threatening conditions.

Keywords: cardiogenic shock, acute myocardial infarction, inotropic drugs, mechanical circulatory support

Published: May 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kettner J. Cardiogenic shock. Interv Akut Kardiol. 2018;17(2):71-74. doi: 10.36290/kar.2018.040.
Download citation

References

  1. Hochman JS, Sleeper LA, Godfrey E, et al. SHOCK Trial Study Group. Should we emergently revascularize occluded coronaries for cardiogenic shock: an international randomized trial of emergency PTCA/CABG - trial design. Am Heart J 1999; 137: 313-321. Go to original source... Go to PubMed...
  2. Jeger RV, Radovanovic D, Hunziker PR, et al. Ten-year trends in the incidence and treatment of cardiogenic shock. Ann Intern Med 2008; 149: 618-626. Go to original source... Go to PubMed...
  3. Thiele H, Jobs A, Ouweneel DM, et al. Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. Eur Heart J 2017. Go to original source... Go to PubMed...
  4. Kettner J, Kautzner J. Akutní kardiologie. Mladá fronta; Praha, 2017.
  5. Harjola VP, Lassus J, Sionis A, et al. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail 2015; 17: 501-509. Go to original source... Go to PubMed...
  6. Pöss J, Köster J, Fuernau G, et al. Risk stratification for patients in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol 2017; 69: 1913-1920. Go to original source... Go to PubMed...
  7. Ibanez B, James S, Agewall S, et al. Group ESCSD. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2017; doi: 10.1093/eurheartj/ehx393 [Epub ahead of print]. Go to original source... Go to PubMed...
  8. Basir M, Schreiber T, Grines C, et al. Effect of early Initiation of mechanical circulatory support on survival in cardiogenic shock. Am J Cardiol 2016; 119: 845-851. Go to original source... Go to PubMed...
  9. Thiele H, Jobs A, Ouweneel DM, et al. Percutaneous short-term active mechanical support device in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. Eur Heart J 2017. Go to original source... Go to PubMed...
  10. O'Neill WW, Schreiber T, Wohns DHW, et al. The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella registry. J Interv Cardiol 2014; 27: 1-11. Go to original source... Go to PubMed...
  11. O'Neill W, Basir M, Dixon S, et al. Feasibility of early mechanical support during mechanical reperfusion of acute myocardial infarct cardiogenic shock. JACC: Cardiovasc Interv 2017; 10: 624-625. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.